Proteomics Study by Serum and Platelet With Neurodegeneration Disease Patients
NCT01564316 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 22
Last updated 2016-04-15
Summary
Using to method of Proteomics, for aims to conquer intractable disease, try to access variety experiment. Biomarker is necessary to develop new diagnosis method and target of treatment.
Conditions
- Biomarker With Neurodegeneration Patients
Sponsors & Collaborators
-
Seoul National University Hospital
lead OTHER
Principal Investigators
-
Manho Kim, Professor · Seoul National University Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2005-05-31
- Primary Completion
- 2014-01-31
- Completion
- 2014-01-31
Countries
- South Korea
Study Locations
More Related Trials
-
Tau PET Imaging With 18F-T807(AV1451) in Neurodegenerative Disorders
NCT04926259 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers
NCT06561906 ·Status: RECRUITING
-
Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects.(Positron Emission Tomograph )
NCT02686216 ·Status: COMPLETED ·Phase: PHASE1
-
A Composite MR Neuroimaging Marker for Alzheimer's Disease
NCT01615666 ·Status: WITHDRAWN
-
PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand
NCT03958630 ·Status: TERMINATED ·Phase: PHASE1
-
Multimodal Markers of Neurodegenerative Disorders at Presymptomatic Stages
NCT06516016 ·Status: NOT_YET_RECRUITING
-
Serum Biomarker of Plaque Vulnerability and Contrast Ultrasound of Carotid Artery
NCT01842490 ·Status: COMPLETED
-
Assessment of Initial Efficacy and Safety of High Intensity Focused Ultrasound 'ExAblate 4000 Type 2' for Blood Brain Barrier Disruption in Patients With Alzheimer's Disease
NCT04526262 ·Status: UNKNOWN ·Phase: NA
-
Imaging of Atherosclerosis With 68Ga-MSA
NCT01889693 ·Status: COMPLETED
-
Multimodal Biomarkers for Diagnosis and Prognosis in VCI
NCT04604600 ·Status: UNKNOWN ·Phase: PHASE3
-
[18F]AV45(Aβ) and [18F]AV1451(Tau)PET/CT in the Diagnosis of Early Pathological Changes of Alzheimer's Disease
NCT06833645 ·Status: RECRUITING
-
Multimodal Biomarkers for Diagnosis and Prognosis in CAA
NCT03969732 ·Status: UNKNOWN ·Phase: PHASE3
-
Radiolabeled TSPO Targeted Molecular Probe in Alzheimer's Disease.
NCT07105956 ·Status: NOT_YET_RECRUITING
-
Multiomic Analysis of Traumatic Brain Injury and Hypertension Intracranial Hemorrhage Lesion Tissue
NCT05778110 ·Status: UNKNOWN
-
New Proteins in Body Fluids as Potential Biomarker for Alzheimer's Disease: a Pilot Study
NCT01773915 ·Status: UNKNOWN
-
Ruijin Neurobank of Alzheimer's Disease and Dementia
NCT05623124 ·Status: RECRUITING
-
Big Data and Genomic Imaging for the Development of Biomarkers and Nanovector Drugs Innovative for Diagnosis and Therapy of Inflammatory Processes in Dementia
NCT05761535 ·Status: COMPLETED
-
Study on Multimodal Imaging and Molecular Imaging Techniques in Degenerative Dementia
NCT06534658 ·Status: RECRUITING
-
New Biomarker for Alzheimer's Disease Diagnostic
NCT01315639 ·Status: COMPLETED ·Phase: NA
-
Establishment of the Chinese Preclinical Alzheimer's Disease Study With Multiple Neuroimaging
NCT06827678 ·Status: RECRUITING
-
Modelling Tau Distribution From DTI With Generative Adversarial Network for Alzheimer's Disease Diagnosis
NCT05020626 ·Status: RECRUITING
-
Biomarker for Pompe Disease (BioPompe)
NCT01457443 ·Status: WITHDRAWN
-
Application of Amyloid PET in Cerebral Amyloid Angiopathy
NCT03542656 ·Status: COMPLETED ·Phase: PHASE3
-
[18F]MC225-PET in Neurodegenerative Disease
NCT05853471 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Modeling the Relationships Between Functional Connectivity and Amyloid Deposition in Alzheimer's Disease
NCT04174287 ·Status: UNKNOWN ·Phase: PHASE2